A rising tide lifts all boats--that might be the most oft-repeated cliché to sum up market sentiment in the life sciences for the last few years. Biotech performance has been very, very good for three years, and med tech performance, while nowhere near as stellar, has been on its own upward trajectory as investors look for a safer way to make money in healthcare.
On Jan. 14, the Animal Health Institute announced that spending by Americans on drugs for animals remained flat at $7.5 billion from 2012 to 2013, the most recent year for which figures are available.
Venture-backed medical device and diagnostics companies are benefiting from a groundswell of investor interest in life sciences that has been spearheaded by great biotech returns for the last several years.
2014 was a big year for medical device companies, with 25 companies filing for IPOs, compared to a mere four the year before.
Kimberly-Clark spinoff Halyard Health, and its suite of protective gear, is a beneficiary of the Ebola fears striking West Africa and the U.S. airwaves. The stock is up a little more than a dollar since Monday's IPO, and stands at $38.72 on the New York Stock Exchange prior to market open today.
Having spent the past 10 months weighing up the merits of a separate listing for its IT subsidiary NNIT, Novo Nordisk has decided it needs to wait a little longer before pulling the trigger.
Endoscopy system maker EndoChoice is the latest in a series of planned big-ticket med tech IPOs. The startup reportedly plans to file for an IPO on Nasdaq to raise $100 million to $150 million and value the company at as much as $600 million.
Two ambitious med tech IPOs are slated to go out in the coming week or so. Both are on their IPO road shows now. Each has an impressive array of investors, high targeted IPO amounts and substantial potential company valuations.
Novo Nordisk is reportedly set to unveil details of an IPO of its IT services business NNIT in the coming days. The Danish drugmaker has spent most of 2014 assessing whether to spin off the unit as an independent company.
Implantable tissue repair player Histogenics has filed for an initial public offering to raise up to $65 million. The financing is to fund an ongoing Phase III trial for its NeoCart, an implant to repair knee cartilage damage. Meanwhile, Molecular diagnostics company AutoGenomics is hoping the third time's the charm with its IPO filing for up to $60 million.